Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum.
OBJECTIVE
To characterize imatinib's effect on endometrial stromal cell (ESC) attachment, proliferation, and invasion in modeled peritoneum.


METHODS
In vitro study.


METHODS
Academic medical center.


METHODS
Twelve normally cycling women.


METHODS
Imatinib treatment in ESCs from women without endometriosis.


METHODS
Rate of ESC attachment, proliferation, and invasion.


RESULTS
Imatinib treatment at 10 μM had no effect on ESC attachment. Treatment with 0.5 μM, 2 μM, and 10 μM of imatinib reduced ESC proliferation by 30%, 72%, and 76%, respectively. The 0.1 μM dose of imatinib had no effect on proliferation. Treatment with 5 μM and 10 μM of imatinib reduced ESC invasion by 30% and 73%, respectively. The 2 μM dose had no effect on invasion.


CONCLUSIONS
Imatinib treatment reduces ESC proliferation and invasion in modeled peritoneum without altering attachment. Imatinib may have a therapeutic role in endometriosis treatment.
Griffith
Jason S
JS
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA. jgriffith@hfi-ivf.com
Binkley
Peter A
PA
Kirma
Namir B
NB
Schenken
Robert S
RS
Witz
Craig A
CA
Tekmal
Rajeshwar R
RR
D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D018929:Cell Culture Techniques; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008954:Models, Biological; D010537:Peritoneum / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D017154:Stromal Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D057705:Transendothelial and Transepithelial Migration / Q000187:drug effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate